Ipsen S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Loew
- Full Time Employees
- 5,358
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 65 Quai Georges Gorse Boulogne-Billancourt France 92100
- IPO Date
- Aug 3, 2012
- Website
- ipsen.com
- Similar Companies
- Business
- Ipsen SA (IPSEY) operates as a global biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, rare diseases, and neuroscience. The company offers a portfolio of specialty care products including Somatuline (lanreotide) for neuroendocrine tumors; Cabometyx (cabozantinib) for renal cell carcinoma, hepatocellular carcinoma, and thyroid cancers; Onivyde (irinotecan liposome injection) for pancreatic and ovarian cancers; Dysport (abobotulinumtoxinA) for movement disorders, spasticity, and aesthetic indications; Bylvay (odevixibat) for rare liver diseases such as progressive familial intrahepatic cholestasis; Tazverik (tazemetostat) for relapsed or refractory follicular lymphoma; and IQIRVO (elafibranor) for primary biliary cholangitis, with additional pipeline assets targeting rare bone disorders, growth disorders, rare neurogenetic conditions, and hematology-oncology indications. Ipsen conducts commercial operations in over 30 countries with products registered in 88 nations, emphasizing Europe, North America, and international markets; it maintains global R&D hubs in France, the U.S., and the U.K., supported by approximately 5,000 employees. Founded in 1929 as a family-owned business by Henri Beaufour and headquartered in Paris, France, Ipsen listed on Euronext Paris in 1983. Recent strategic developments include the October 2025 announcement to acquire ImCheck Therapeutics for up to €1 billion to bolster its oncology pipeline with ICT01, a gamma delta T-cell activator for solid tumors; expansion of partnerships in 2024 with Skyhawk Therapeutics on RNA modulators for rare neurological diseases, Marengo Therapeutics on T-cell engagers, and others such as Foreseen, Sutro Biopharma, Biomunex, and Day One Biopharmaceuticals for ex-U.S. rights to Ojemda (tovorafenib); prior acquisitions of Albireo in 2023 for Bylvay, Epizyme in 2022 for Tazverik, and Clementia in 2019 for palovarotene in rare bone diseases; divestment of its Consumer Healthcare business to Mayoly Spindler in 2022 to sharpen focus on specialty care; and upgrades to 2025 guidance projecting around 10% total sales growth driven by oncology and rare disease momentum, alongside approvals such as Cabometyx for advanced neuroendocrine tumors in the EU and Bylvay in Japan.
Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications Transcript
Ipsen S.A. – Evolution of the composition of the Board of Directors
Annual General Meeting of Ipsen S.A. held on 13 May 2026
Ipsen S.A. (IPSEY) Q1 2026 Earnings Call Transcript
IPSEN (OTCMKTS:IPSEY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
IPSEN (OTCMKTS:IPSEY) Shares Gap Up – What’s Next?
IPSEN (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average – Time to Sell?
IPSEN (OTCMKTS:IPSEY) Shares Pass Above 200 Day Moving Average – What’s Next?
Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Ipsen S.A. - Initiation of the share buy-back program
Ipsen S.A. - Annual General Meeting held on 21 May 2025
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen